Company intelligence / Profile preview

Guangzhou Anhao Pharmaceutical Technology Co., Ltd.

Guangzhou, Guangdong Sheng, China

Ownership: Private
Development stage: Preclinical

Overview

Guangzhou Anhao Pharmaceutical Technology Co., Ltd. develops small molecule drugs targeting oncology and digestive system disorders. Its lead asset, DX1002, a dual CDH5 and tubulin inhibitor, has reached Phase II clinical trials for advanced gastric carcinoma, hepatocellular carcinoma, stomach cancer, and advanced malignant solid neoplasms in China. No public clinical results are available as of the latest update.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

DX1002

Unknown

Beyond the preview

Go deeper on Guangzhou Anhao Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Anhao Pharmaceutical Technology Co., Ltd..

Explore the full profile